A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women With Recurrent, Persistent or Metastatic Endometrial Cancer
This phase II trial studies how well olaparib and cediranib maleate work in treating patients with endometrial cancer that has come back, does not respond to treatment, or has spread to other places in the body.
Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- IRB Number: 1904481446 (NRG-GY012)
- Research Study Identifier: TX10173
- Principal Investigator: Jeanne Schilder, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required